Guidelines on the management of acute myeloid leukaemia in adults.
about
Low dose cytarabine monotherapy for acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaThe role of maintenance therapy in acute promyelocytic leukemia in the first complete remissionHypomethylating agents for adult patients with acute myeloid leukaemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaOral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid LeukemiaDeregulation of mitochondrial ATPsyn-β in acute myeloid leukemia cells and with increased drug resistanceSpotlight on histamine dihydrochloride in acute myeloid leukaemia.Decitabine: a review of its use in older patients with acute myeloid leukaemia.The European Medicines Agency Review of Decitabine (Dacogen) for the Treatment of Adult Patients With Acute Myeloid Leukemia: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Southwestern Oncology Group pretreatment risk criteria as predictive or prognostic factors in acute myeloid leukemiaComparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.Guidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: what is available in 2010?Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.Significant reduction of red blood cell transfusion requirements by changing from a double-unit to a single-unit transfusion policy in patients receiving intensive chemotherapy or stem cell transplantationEvaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapyOral Maintenance Chemotherapy with 6-Mercaptopurine and Methotrexate in Patients with Acute Myeloid Leukemia Ineligible for TransplantationCryoprecipitate therapy.New considerations in the design of clinical trials for the treatment of acute leukemia.Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experienceOral Debio1143 (AT406), an antagonist of inhibitor of apoptosis proteins, combined with daunorubicin and cytarabine in patients with poor-risk acute myeloid leukemia--results of a phase I dose-escalation study.Management of febrile neutropenia in a patient with acute leukemia.Acute leukemia in women.Acute myeloid leukaemia in the elderly: a review.Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations.The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia.Molecular markers in acute myeloid leukaemia.Current standard treatment of adult acute promyelocytic leukaemia.Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia.Therapeutics formulated to target cancer stem cells: Is it in our future?The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.Acute leukemia during pregnancy: an investigative survey of the past 11 years.Platelet transfusions in haematology patients: are we using them appropriately?Characterization and analysis of the outcome of adults with acute myeloid leukemia treated in a Brazilian University hospital over three decades.Prophylactic use of granulocyte colony-stimulating factor after induction chemotherapy in patients with newly diagnosed acute myeloid leukemia may increase the complete remission rate: a meta-analysis of five randomised controlled trials.Survival differences in childhood and young adult acute myeloid leukemia: A cross-national study using US and England data.Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia.
P2860
Q24186270-BC7C98C7-3BF0-4FFF-9C0E-8DAC9059226FQ24186284-831E7ABB-5D65-49C5-B4E2-34E9F2517BD5Q24200224-F2B19C21-B839-4A02-9CB7-1CC54E7C43A8Q24234645-651AB3DA-CBCB-4922-B400-B329D876B8D4Q24234680-B444772E-534B-44BE-B562-24F0C6D3C1AAQ28084813-0847EC8A-C2F4-4ECF-8032-67DD744ED36BQ28538139-4C98F626-1637-4F5B-922C-D3BBCB518825Q33394612-5442768C-A31E-47FF-BA2C-76126362485FQ33407030-442350F2-33B3-4675-B834-7DC62F2AF720Q33431584-1EABCA94-4DF5-46A8-BFC5-FEFE8CF29B26Q33555627-75607AED-5CE1-46B1-9AD9-48926005112BQ33598706-F311B396-FC06-4093-B872-31E20F1C0C4BQ34620456-ED7DC6F7-EBE1-4749-B38B-8FCDA30D93E3Q35010346-0A63321E-1080-4C61-9F7E-69C1BCAB0A75Q35096486-B882CFAC-C8B8-4F3C-B2C6-45F6757A308BQ35643058-F453B2E3-C80D-4D7A-9904-E433966E97C6Q35886215-44C1AB95-B547-48F1-B751-D4D92A95DD5CQ36075433-23A87CDE-0BAE-4EF6-AB1A-4FF818FD9402Q36232259-F7A029DE-DA07-421B-A79D-0409A692975EQ36641721-51781768-06CA-456E-AE0C-8E321FB14389Q36713551-9B298B7A-308D-4609-8376-AE6C4A3B2616Q37267506-AD1455DE-F9D3-4086-A435-AADF84646C2CQ37641844-78FDC11F-208A-4D7E-B451-7EA4A4ABA8B9Q37699362-2AF1C045-7A6E-478A-A271-497EA5970456Q37840260-0C907BE3-228C-4BB3-B5F4-692AA29DFE00Q37842488-1E005A80-1E7F-4C24-ABCC-83C5948F52FAQ37952402-FCE986DE-753D-4D35-9F27-4E67AA38B87CQ38026007-635E4938-5637-43C9-9A8D-C1CC067870F8Q38674575-6DB92F83-57C7-473D-9641-BC7F8305042EQ38918850-137BA1E3-44F6-4954-A1B5-EADB5A3C59D7Q38983626-6384E28A-4C24-4ADC-ADFD-6CDAABCD3E58Q39198718-4101E9B9-DF9B-4B02-94A1-11D724965861Q39767667-B88F00D7-C94E-4525-AAB6-0E2B5E04C4EDQ40827250-4F76468E-6A94-420A-A86C-5B4E16E5BE6DQ43892085-91E82B19-4265-4574-AE9E-3653D05F7BF3Q47405698-B43BAF26-E1DC-42EE-9E7A-3244702F60B1Q51033194-42A399B3-A020-4D9C-BE12-342801B72B7FQ51784425-E645B5DE-D59D-4478-AF69-E09BB54EFD9DQ52350414-501B0849-E30F-4BB9-B137-A86B6D82CE33Q53194151-69C43053-16B2-4FB6-9C16-74122A0F6AC7
P2860
Guidelines on the management of acute myeloid leukaemia in adults.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Guidelines on the management of acute myeloid leukaemia in adults.
@ast
Guidelines on the management of acute myeloid leukaemia in adults.
@en
type
label
Guidelines on the management of acute myeloid leukaemia in adults.
@ast
Guidelines on the management of acute myeloid leukaemia in adults.
@en
prefLabel
Guidelines on the management of acute myeloid leukaemia in adults.
@ast
Guidelines on the management of acute myeloid leukaemia in adults.
@en
P2093
P2860
P1476
Guidelines on the management of acute myeloid leukaemia in adults.
@en
P2093
C Craddock
D Grimwade
D W Milligan
J Homewood
J O Cullis
K Campbell
K Wheatley
P2860
P304
P356
10.1111/J.1365-2141.2006.06314.X
P407
P577
2006-10-10T00:00:00Z